Skip to main content

Measuring the Potency of a Stem Cell Therapeutic

  • Protocol
  • First Online:
Stem Cell Protocols

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1235))


The potency of a drug is one of the most important parameters of a therapeutic. Besides providing the basis for manufacturing consistency and product stability, the potency can predict product failure or toxicity due to incorrect potency, provide release criteria, and the dose that will ensure that it can be used as intended. Recently, cellular therapeutics, in particular, stem cell therapy products, have being designated as “drugs” by regulatory agencies if they produce a systemic effect in the patient. Regulatory agencies are becoming increasingly stringent with respect to the manufacture, production, and testing of these products prior to being used in a patient. A clear understanding of what potency is and how it can be measured should help erase the misunderstandings and misconceptions that have accrued within the cellular therapy field. This protocol describes how the potency of hematopoietic stem cell therapy products is determined. The same principles apply to any proliferating stem cell therapeutic product.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others


  1. U.S. Food and Drug Administration (FDA) (2011) Guidance for industry. Potency tests for cellular and gene therapy products.

  2. European Medicines Agency (EMA) (2008) Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer.

  3. U.S. Food and Drug Administration (FDA) (2009) Guidance for industry. Minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution for specified indications. BloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM187144.pdf

  4. Rich IN (2013) Potency, proliferation and engraftment potential of stem cell therapeutics: the relationship between potency and clinical outcome for hematopoietic stem cell products. J Cell Sci Ther S13:001. doi:10.4172/2157-7013.S13-001

    Google Scholar 

  5. Page KM, Zhang L, Mendizabal A et al (2011) Total colony-forming units are a strong, independent predictor or neutrophil and platelet engraftment after unrelated cord blood transplantation: a single center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant 17:1362–1374

    Article  PubMed  Google Scholar 

  6. Hall KM, Rich IN (2011) Hematopoietic stem cell potency for cellular therapeutic transplantation. In: Pelayo R (ed) Advances in hematopoietic stem cell research. InTech, Croatia, pp 384–406

    Google Scholar 

  7. Rich IN (2013) The difference between stem cell viability and potency: a short guide for parents and patients. Parent’s guide to cord blood foundation.

  8. Page KM, Zhang L, Mendizabal A (2012) The cord blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation (CME). Transfusion 52:272–283

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Bradley TR, Metcalf D (1966) The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44:287–299

    Article  CAS  PubMed  Google Scholar 

  10. Pluznik DH, Sachs J (1966) The induction of clones of normal mast cells by a substance from conditioned medium. Exp Cell Res 43:553–563

    Article  CAS  PubMed  Google Scholar 

  11. Iscove NN, Sieber F, Winterhalter KH (1974) Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol 83:309–320

    Article  CAS  PubMed  Google Scholar 

  12. Rich IN (2003) In vitro hematotoxicity testing in drug development: a review of past and future applications. Curr Opin Drug Discov Dev 6:100–109

    CAS  Google Scholar 

  13. Rich IN (2007) High-throughput in vitro hemotoxicity testing and in vitro cross-platform comparative toxicity. Expert Opin Drug Metab Toxicol 3:295–307

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ivan N. Rich .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this protocol

Cite this protocol

Harper, H., Rich, I.N. (2015). Measuring the Potency of a Stem Cell Therapeutic. In: Rich, I. (eds) Stem Cell Protocols. Methods in Molecular Biology, vol 1235. Humana Press, New York, NY.

Download citation

  • DOI:

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1784-6

  • Online ISBN: 978-1-4939-1785-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics